SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported fourth-quarter profit of $137 million.
The San Diego-based company said it had net income of $1.06 per share. Earnings, adjusted for one-time gains and costs, came to $1.26 per share.
The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of $1.16 per share.
The biopharmaceutical company posted revenue of $298 million in the period, also surpassing Street forecasts. Six analysts surveyed by Zacks expected $284 million.
For the year, the company reported profit of $444.1 million, or $3.43 per share. Revenue was reported as $1.02 billion.
Halozyme Therapeutics expects full-year earnings in the range of $4.95 to $5.35 per share, with revenue in the range of $1.15 billion to $1.23 billion.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HALO at https://www.zacks.com/ap/HALO
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.